Background: Patients with lung cancer present to the emergency department (ED) in a variety of ways. Symptoms are often nonspecific and can lead to a delay in diagnosis. Here, a lung cancer mimicked two illnesses, adding to the diagnostic complexity. This case highlights diagnostic pitfalls as well as advantages and limitations of imaging utilized in the emergency setting.
Case Report: We report a case of an occult lung cancer occluding a pulmonary vein, which at first mimicked pneumonia and later a pulmonary embolism (PE) and arterial lung infarction. The patient presented to the ED with cough and a lung opacity on chest radiograph that was treated with antibiotics. However, recurrent visits to the ED with similar complaints were further investigated with computed tomography angiogram (CTA). At first the scan was considered positive for PE. Further inspection revealed that the CTA findings were not typical for PE, but rather a slow flow state likely caused by an occult mass occluding a pulmonary vein with venous infarction. Biopsy revealed a lung adenocarcinoma. In addition to the case presentation, the typical signs of PE on CTA with correlating images and diagnostic pitfalls are discussed. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This case report raises two themes that can be of interest to emergency physicians. The first is that lung cancer has many guises. Here it mimicked two distinctly different diseases, pneumonia and PE. The second is that, although CTA is highly sensitive and specific for diagnosing PE, it has limitations that may lead to false positive readings. When clinical signs and symptoms fail to correlate with the imaging diagnosis, alternative explanations should be sought.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jemermed.2015.12.019 | DOI Listing |
JAMA Intern Med
January 2025
Stanford Prevention Research Center, Department of Medicine, School of Medicine, Stanford University, Palo Alto, California.
JAMA Intern Med
January 2025
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.
Importance: The optimal configuration of a smoking cessation intervention in a lung cancer screening (LCS) setting has not yet been established.
Objective: To evaluate the efficacy of 3 tobacco treatment strategies of increasing integration and intensity in the LCS setting.
Design, Setting, And Participants: In this randomized clinical trial, LCS-eligible current smokers were randomized into 3 treatments: quitline (QL), QL plus (QL+), or integrated care (IC).
Int J Clin Pharm
January 2025
Center for Health Policy and Technology Evaluation, Peking University Health Science Center, Beijing, 100191, China.
Background: Lung cancer is the leading cause of cancer-related deaths in China, and pembrolizumab shows differential efficacy in advanced non-small cell lung cancer (NSCLC) with different PD-L1 expression levels.
Aim: To assess the cost-effectiveness of PD-L1 testing associated with pembrolizumab for first-line treatment of NSCLC from the perspective of Chinese healthcare system.
Method: Over a lifetime horizon, a three-state partitioned survival model was developed to assess the cost-effectiveness of PD-L1 testing and no PD-L1 testing.
Cancer Cytopathol
February 2025
Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Background: Fumarate hydratase-deficient renal cell carcinoma (FHRCC) is an aggressive carcinoma that typically presents as advanced-stage disease. Prompt recognition of FHRCC is critical for appropriate clinical care and genetic counseling for patients and family members. However, diagnosing FHRCC from cytology specimens is challenging, with limited characterization and no reports describing prospectively identified cases.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!